What are the causes of hypertrophic obstructive cardiomyopathy, how is it diagnosed on echocardiography, and how should it be managed?

Hypertrophic Obstructive Cardiomyopathy: Causes, Echocardiographic Diagnosis, and Management

Etiology

HOCM is a genetic cardiac disorder caused by sarcomere gene mutations, most commonly in MYBPC3 and MYH7 genes, resulting in left ventricular hypertrophy with dynamic outflow tract obstruction. 1, 2

• The disease has a prevalence of 1:500 in the general population 2
• Pathophysiology involves hypercontractility from increased actin-myosin cross-bridges, myocyte hypertrophy and disarray, interstitial fibrosis, and coronary microvascular dysfunction 3
• Structural abnormalities include asymmetric septal hypertrophy, systolic anterior motion (SAM) of elongated mitral valve leaflets, and displaced or hypertrophied papillary muscles 3
• Alternative causes must be excluded: athletic remodeling, uncontrolled hypertension, renal disease, infiltrative diseases, maternal gestational diabetes in neonates 1

Echocardiographic Diagnosis

Transthoracic echocardiography (TTE) is the primary diagnostic modality and must demonstrate asymmetric septal hypertrophy ≥15 mm (or ≥13 mm with family history), SAM of the mitral valve, and LVOT obstruction with peak gradient ≥30 mm Hg. 1, 4

Key Diagnostic Features:

• Wall thickness: Maximal wall thickness ≥15 mm is diagnostic (≥13 mm if positive family history); this measurement is essential for phenotype severity and sudden cardiac death risk stratification 1, 4
• LVOT gradient: Peak gradient ≥30 mm Hg defines obstruction; ≥50 mm Hg is hemodynamically significant and triggers consideration for advanced therapies 4, 5
• SAM: Systolic anterior motion of the mitral valve causes dynamic obstruction and is a hallmark finding 4, 3
• Mitral regurgitation: Typically mid-to-late systolic, directed posteriorly or laterally due to impaired leaflet coaptation 4
• Papillary muscle abnormalities: Anteriorly displaced or anomalous papillary muscle insertion frequently identified 4

Provocative Testing Requirements:

For patients with resting LVOT gradient <50 mm Hg, provocative maneuvers are mandatory because up to 50% of obstructive physiology can be missed on resting studies alone. 1, 4

• Use Valsalva maneuver, standing from squatting position, or exercise echocardiography 1, 4
• Do NOT use dobutamine provocation due to limited specificity; physiological maneuvers are preferred 4
• Exercise TTE is recommended for symptomatic patients without resting or provocable gradient ≥50 mm Hg 1

Physical Examination Findings:

• Harsh crescendo-decrescendo systolic murmur that increases with Valsalva and standing 1
• Prominent apical point of maximal impulse, abnormal carotid pulse, fourth heart sound 1
• Patients without LVOTO may have normal examination 1

Management Algorithm

Step 1: Initial Medical Therapy for Symptomatic Patients with Gradient ≥50 mm Hg

First-line pharmacotherapy consists of non-vasodilating beta-blockers or non-dihydropyridine calcium channel antagonists (verapamil). 2

• Beta-blockers alleviate dyspnea, improve quality of life, and lower LVOT gradient 2
• Verapamil increases physical resilience and lowers LVOT gradient 2
• Common side effects: bradycardia, hypotension, risk of AV nodal blockade 2

Step 2: Advanced Medical Therapy

Mavacamten (myosin inhibitor) is indicated if conventional therapy fails; it lowers LVOT gradient and improves quality of life. 2

• Critical caveat: 7-10% of patients experience reversible reduction of left ventricular ejection fraction to <50%, requiring monitoring 2

Step 3: Septal Reduction Therapy

Consider septal reduction therapy (surgical myectomy or alcohol septal ablation) if medical therapy fails to control symptoms in patients with gradient ≥50 mm Hg. 1, 2

Surgical Myectomy:

• Intraoperative TEE is mandatory to assess mitral valve anatomy, adequacy of septal myectomy, and monitor for complications (ventricular septal defect, new aortic insufficiency) 1, 4
• Thorough mitral valve examination before surgery determines optimal procedural approach 4

Alcohol Septal Ablation:

• Use ultrasound-enhancing contrast injection of candidate septal perforators with TTE or TEE 1, 4
• Ultrasound-enhancing agents improve procedural success, shorten intervention time, reduce infarct size, and lower pacemaker requirement 4

Step 4: Post-Procedural Monitoring

TTE within 3-6 months after septal reduction therapy is required to evaluate procedural results. 1

• Assess: septal thinning, reduction of LVOT gradient, residual SAM, degree of mitral regurgitation, aortic insufficiency, ventricular septal defects 4

Step 5: Ongoing Surveillance

Repeat TTE every 1-2 years for stable patients to assess myocardial hypertrophy, dynamic LVOTO, mitral regurgitation, and myocardial function. 1

• Repeat TTE immediately for any change in clinical status or new clinical event 1

Additional Management Considerations

• Sudden cardiac death risk: Patients at increased risk require cardioverter-defibrillator implantation 5
• Atrial fibrillation: Life-long anticoagulation is indicated after first episode 5
• Family screening: First-degree relatives require TTE as part of initial screening and periodic follow-up 1
• Genotype-positive, phenotype-negative individuals: Echocardiography every 1-2 years in children/adolescents, every 3-5 years in adults 1

Common Pitfalls

• Missing latent obstruction: Failure to perform provocative maneuvers when resting gradient <50 mm Hg misses 50% of obstructive cases 4
• Misdiagnosing acute coronary syndrome: HOCM can present with chest pain, ECG changes, and elevated cardiac biomarkers mimicking myocardial infarction; cardiac auscultation revealing systolic murmur is crucial 6
• Post-procedural elevated gradients: 22% of patients show elevated peak gradients after myectomy without demonstrable LVOT obstruction; 3D echocardiography can differentiate true obstruction from residual functional gradients 7